정신분열병에 대한 리스페리돈의 효과 및 안정성

이민수,김용구,김영훈,연병길,오병훈,윤도준,윤진상,이철,정희연,강병조,김광수,김동언,김명정,김상훈,김희철,나철,노승호,민경준,박기창,박두병,백기청,백인호,손봉기,손진욱,양병환,양창국,우행원,이정호,이종범,이홍식,임기영,전태연,정영조,정영철,정인과,정인원,지익성,채정호,한상익,한선호,한진희,서광윤 大韓神經精神醫學會 1998 신경정신의학 Vol.37 No.1

연구목적 : 본 시험의 목적은 임상시험 시작전에 연구자들을 대상으로 PANSS Workshop을 통하여 PANSS, ESRS에 대한 국내에서의 표준화 작업을 구축하고 새로운 정신병 치료제인 리스페리돈의 효과와 안정성을 재확인하여 리스페리돈 사용에 대한 적정화를 이루는데 있다. 연구방법 : 1996년 4월부터 1996년 9월까지 국내 39개 대학병원 정신과에 입원중인 혹은 증상이 악화되어 입원하는 정신분열병 환자 377명을 대상으로 다시설 개방 연구를 시행하였다. 1주일간의 약물 배설기간을 가진후, 리스페리돈을 8주간 투여하였고, 기준점, 1주, 2주, 4주, 그리고 8주후에 평가되었다. 용량은 제1일에는 리스페리돈 1mg씩 1일 2회, 제2일에는 2mg씩 1일 2회, 제3∼7일에는 3mg씩 1일 2회 투여하였다. 이후 환자의 임상상태에 따라 임의로 증량할 수 있으며, 최대 일일 16mg을 초과하지 않도록 하였다. 추체외로 증상을 조절하기 위한 투약을 허용하였다. 임상증상 및 부작용의 평가는 PANSS(Positive and Negative Syndrome Scale), CGI(Clinical Global Impression) 그리고 ESRS(Extrapyramidal Symptom Rating Scale)을 사용하였다. 연구결과 : 377명중 343명(91%)이 8주간의 연구를 완결하였다. 치료 종결시점인 8주후 PANSS 총점수가 20% 이상 호전된 경우를 약물 반응군으로 정의할때, 약물반응군은 81.3%였다. 리스페리돈에 반응하는 예측인자로는 발병연령, 이전의 입원 횟수, 유병기간이 관련 있었다. 리스페리돈은 1주후부터 PANSS양성, 음성, 및 일반정신병리 점수상에 유의한 호전을 보여 효과가 빨랐다. CGI의 경우도 기준점에 비해 1주후부터 유의한 감소를 나타내었다. ESRS의 경우, 파킨슨 평가점수는 기준점과 비교해 투여 1주, 2주, 4주후 유의하게 증가되었다가 8주후 기준점과 차이가 없었다. Dystonia 평가점수는 1주후만 유의한 증가를 보였으며, dyskinesia 평가점수는 유의한 차이가 없었다. 혈압, 맥박수의 생명징후 및 일반 혈액학 검사, 생화학적 검사, 심전도 검사에서 유의한 변화는 없었다. 결 론 : 이상의 다시설 개방 임상 연구를 통해 리스페리돈은 정신분열병 환자에서 양성증상뿐만 아니라 음성증상 및 전반적인 증상에도 효과적인 것으로 사료된다. 보다 명확한 평가를 위해서는 다른 항정신병약물과의 이중맹검 연구가 필요할 것으로 생각되며, 또한 장기적 치료에 대한 평가도 함께 이루어져야 하겠다. Objective : The purpose of this study was to investigate the efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. Method : This multicenter open study included 377 schizophrenic patients drawn from 39 university hospitals. After a wash-out period of 1 week, the schizophrenic patients were treated with risperidone for 8 weeks and evaluated at 5 points ; at baseline, and 1, 2, 4 and 8 weeks of treatment. The dose was increased from 2mg/day(1mg twice daily) to 6mg/day(3mg twice daily) during the first week and adjusted to a maximum of 16mg/day over the next 7 weeks according to the patient's clinical response. Medication to control extrapyramidal symptoms was permitted. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. Results : 343(91%) of 377 patients completed the 8-week trial period. Clinical improvement, as defined by a 20% or more reduction in total PANSS score at end point, was shown by 81.3% of patients. The predictors of response to risperidone were associated older age, shorter duration of illness, fewer previous hospitalization. Risperidone had rapid onset of action ; a significant decrease of the total PANSS and three PANSS factor(positive, negative, general), and CGI was already noticed at the end of first week. For the ESRS, parkinsonism rating scores were significantly increased until week 4 comparing with baseline. Dystonia rating scores were significantly increased until week 1, and dyskinesia rating scores were not significantly changed during the study. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial. Conclusions : This study suggests that risperidone is generally safe and effective against both the positive and negative symptoms in our group of patients.

장기적 트립토판 결여식이 생쥐의 유해감각예민도에 미치는 영향

서영대,박제민,김명정,전명호,양구범,장세헌,강철중,김정태,김용식 대한생물치료정신의학회 2000 생물치료정신의학 Vol.6 No.1

The depressive patients can be divided into two subgroups by presence and absence of pain symptoms. Those without pain symptoms have blunted pain sensitivity whereas those with pain have normal range of pain sensitivity, and are clinically characterized by anxiety and irritability. The aim of the study is to test if these clinical profiles of the depressives with pain symptoms are related with reduced level of brain serotonin(5-HT). Forty four mice were randomly divided into two groups : one group to be bred with tryptophan free diet and the other with normal control diet, each for 4 weeks. Before the beginning of the breeding period, measured were locomotor activity by open field test, anxiety by elevated plus maze and nociceptive sensitivity by tail flick test, before and after forced swimming(FS). During each FS, duration of immobilization was also measured. The sable sets of measurements were repeated at the end of the breeding period. The brain 5-HT and 5-hydroxyindoleacetic acid(5-HIAA) were measured by high performance liquid chromatography. The results were as follows 1.Four weeks of tryptophan free diet reduced significantly body weight, brain weight, and levels of 5-HT and 5-HIAA in the whole brain. 2.Tryptophan depletion did not influence basal nociceptive sensitivity as measured by tail flick latency before FS. The normal blunting of the pain sensitivity induced by forced swimming was preserved in the tryptophan depleted group. 3.Tryptophan depletion did not influence general locomotor activity in open field. 4.Tryptophan depletion increased significantly time spent on the open arms at the elevated plus maze test done before FS. This anxiolytic-like effect was reduced by FS. 5.Tryptophan depletion did not influence duration of immobilization during FS. From these results, it is suggested that the genesis of the depression with pain symptoms is not medicated by quantitative reduction of brain serotonin

Matlab을 이용한 유성음 성도단면의 실시간 분석기 구현

권오영,박일서,조철우 국립7개대학공동논문집간행위원회 2003 공업기술연구 Vol.3 No.-

In this paper we tried to compute the shape of the vocal tract from the input speech in real-time. To implement the real-time process MATLAB Data Acquisition Toolbox was used. Implemented program can compute and display the shape of the vocal tract from the various input speech signal.

사이버곤충생태원 데이터베이스 시스템 개발

최영철,박해철,서민수 한국농업정보과학회 2000 농업정보과학 Vol.2 No.1

이 사이트는 웹(Web) 데이타베이스(DB) 연동기술을 적용하여 웹서비스를 지원하기 위해 곤충 및 식물 생태 정보를 경관별 및 시기별로 데이타베이스화하여 일반인이 곤충 생태원을 가상공간인 웹 상에서 쉽게 접할 수있도록 개발 된 사이버곤충생태원(Cyber Insect Garden)으로서 국내 최초로 개설하여 인터넷상(http://niast.go.kr/cig)에서 운용하고 있다. 곤충 및 식물 정보를 체계적으로 데이터베이스화아여 숲ㆍ계곡ㆍ연못ㆍ바닷가ㆍ풀밭ㆍ마을의 경관과 시기에 따라 주요 기주 식물과 관련된 곤충의 사진과 곤충을 쉽게 이해할 수 있도록 자세한 설명을 제공함으로써 일반인들에게 생동감있는 곤충 및 관련 기주식물 생태에서 대하서 간접적으로 경험할 수 있게 하였다. 또한 방대한 곤총 및 식물 생태 정보 데이터를 제공함으로써 40-50대는 어린시절의 향수를 느낄 수 있고 청소녀들엑는 자연학습체럼을 니터넷을 통해 경험하게 함으로꺼 정서 순화에도 도움이 되도록 하였다. To develop World Wide Web servire of Cyber Insect Garden(CIG) linked with database, we col-lected ecological information data of insect and host plant. This site can be accessed easily by the general public. Insects and host plants can be linked with various scenes and seasons. CIG was the first site developed in Korea and its Web site address is http://www.mast.go.kr/cig. As database information consist of text data and images of insects and host plants for the general public, we access to lots of ecological insects and host plants informa-tions. Therefore, all netizens can experience them indirectly and feel their childhood homesickness.

자궁근종에서 Phospholipase C 동종효소들의 발현에 관한 연구

윤혜원,류임주,김창미,심재철,서영석 대한해부학회 1995 Anatomy & Cell Biology Vol.28 No.4

대장통과시간 측정용 방사선 비투과성 표지자인 KolomarkTM의 국내 개발

김지은,이풍렬,김영호,성인경,심상군,김재준,고광철,최규완,임효근,서수원 대한소화관운동학회 1999 Journal of Neurogastroenterology and Motility (JNM Vol.5 No.2

D-Amino Acid Aminotransferase 활성보유 고온성미생물의 탐색 및 분류학적 특성 연구

곽미선,이승구,정상철,서승현,이재흥,전영중,김영호,성문희 충남대학교 약학대학 의약품개발연구소 1999 藥學論文集 Vol.15 No.-

To acquire an industrially useful biocatalyst for the enzymatic synthesis and production of various D-amino acids, 1,300 thermophiles isolated from the soil of Korea were analyzed for D-amino acid aminotransferase (D-AAT) activity. The enzyme activity was found from 110 strains of isolated thermophiles revealing its wide occurrence in thermophiles. Enzyme activity and thermal stability of the D-AAT producers were compared. Finally we have selected four thermophiles as producers of potent biocatalysts for the D-amino acid production; two therrnophiles, Bacillus sp. LK-I and LK-2, having higher specific activity and two thermophiles, B. stearothermophilus KL-01 and Bacillus sp. KLS-0l, having higher thermal stability than the D-AAT producers. Taxonomic and physiological characteristics of the four isolated thermophiles were described herein.

Head-Space SPME에 의한 생체시료 중 메스암페타민류 분석(Ⅲ)

박미정,최상길,손행자,최화경,최영남,허상철,박종서,정희선 內務部 國立科學搜査硏究所 2002 國立 科學 搜査 硏究所 年報 Vol.34 No.-

Diagnosis and Treatment of Lupus Nephritis: Survey Results on Four Important Issues

( Young Bin Joo ),( Yoon Kyoung Sung ),( Yong Beom Park ),( Chang Hee Suh ),( Seung Cheol Shim ),( Young Ho Lee ),( Ji Soo Lee ),( Hye Soon Lee ),( Hoon Suk Cha ),( Sang Cheol Bae ) 대한류마티스학회 2013 대한류마티스학회지 Vol.20 No.3

Objectives. To investigate the perception of and treatment pattern with regard to the four important issues in the management of lupus nephritis (LN), and to identify which parts of the LN treatment are difficult for physicians to carry out in clinical practice. Methods. Four steps were carried out: pre-survey, LN symposium, post-survey, and meeting after the symposium.The two surveys were conducted with the same contents regarding renal biopsy, induction and maintenance treatment for class III and IV LN, and treatment for class V LN. The results of the first survey and the changes in opinion reflected in the second survey were comparatively analyzed. Results. In the first survey, most of the respondent physicians replied that they would immediately conduct biopsy in the case of significant proteinuria. For the induction treatment of class III and IV LN, most of the respondent physicians selected high-dose cyclophosphamide. Mycophenolate mofetil and steroid combination therapy were selected for the maintenance treatment, and tacrolimus for the treatment of class V LN. There was a controversy in the drug selection, however, especially on the maintenance treatment of class III and IV LN and on the treatment of non-responsive class V LN. Conclusion. Some discrepancies were found in the treatment of LN in the real world. Although no recommendation was made for Korean LN patients in this study, the study results will help physicians select the most reasonable treatment for Korean LN patients based on experts` experiences and objective evidence.

Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis

( Young Mo Kang ),( Young-eun Park ),( Won Park ),( Jung-yoon Choe ),( Chul-soo Cho ),( Seung-cheol Shim ),( Sang Cheol Bae ),( Chang-hee Suh ),( Hoon-suk Cha ),( Eun Mi Koh ),( Yeong-wook Song ),( Bi 대한내과학회 2018 The Korean Journal of Internal Medicine Vol.33 No.6

Background/Aims: The objective of this study was to determine the efficacy and safety of add-on therapy with certolizumab pegol (CZP) in active rheumatoid arthritis (RA) patients of a single ethnicity. Methods: In this 24-week, phase 3, randomized, double-blind, placebo-controlled trial, eligible patients (n = 127) were randomized 2:1 to subcutaneous CZP + methotrexate (MTX; 400 mg at week 0, 2, and 4 followed by 200 mg every 2 weeks) or placebo + MTX. Results: At week 24, the American College of Rheumatology criteria for 20% (ACR20) response rate was significantly greater with CZP + MTX than with placebo (66.7% vs. 27.5%, p < 0.001). Differences in ACR20 response rates for CZP vs. placebo were significant from week 1 (p < 0.05) and remained significant through week 24. The CZP group reported significant improvement in physical function and disability compared to the placebo group (p < 0.001) at week 24, as assessed by Korean Health Assessment Questionnaire-Disability Index (KHAQ-DI). Post hoc analysis indicated that the proportion of patients who had ACR70 responses, Disease Activity Score 28 (DAS28) low disease activity, and DAS28 remission at week 24 was greater in CZP + MTX-treated patients who achieved a decrease in DAS28 ≥ 1.2 (43.8%) at week 4 than in nonresponders. Among 18 (22.2%) and 14 patients (35.0%) in CZP and placebo groups who had latent tuberculosis (TB), none developed active TB. Most adverse events were mild or moderate. Conclusions: CZP treatment combined with MTX in active RA patients with moderate to severe disease activity and an inadequate response to MTX resulted in rapid onset of efficacy, which is associated with better clinical outcome at week 24 and has an acceptable safety profile, especially in an intermediate TB-burden population.